Company Goals:
Clinical evaluation of L-Annamycin to treat children with relapsed or refractory acute lymphocytic or acute myelocytic leukemia
Clinical development of L-Annamycin as a potential treatment for adults with relapsed or refractory acute lymphocytic leukemia
Clinical development of Atiprimod as a treatment for patients with advanced carcinoid cancer
Clinical development of Atiprimod as a potential new treatment for patients with relapsed multiple myeloma
Preclinical development of Guanilib, Callisto’s first-in-class drug to treat inflammatory bowel diseases